Cellectar Biosciences, Inc.
CLRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001279704
No open-market purchases or sales by Cellectar Biosciences, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $9.08M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Cellectar Biosciences, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 35 | 1 | 30 | −4 |
| Shares | 14.0M | 30.0K | 5.10M | −8.88M (−63.5%) |
| Value | $30.0M | $64.2K | $1.52M | −$28.4M (−94.9%) |
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (6)
Institutions that held Cellectar Biosciences, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Squarepoint Ops LLC | 520,240 | $155.6K | 0.00% |
| Two Sigma Investments, LP | 71,119 | $21.3K | 0.00% |
| BNP Paribas Arbitrage, SA | 16,815 | $5.03K | 0.00% |
| Commonwealth Equity Services, LLC | 12,051 | $4.00K | 0.00% |
| Citigroup Inc | 660 | $197 | 0.00% |
| SBI Securities Co., Ltd. | 400 | $120 | 0.00% |
Sold out (10)
Institutions that held Cellectar Biosciences, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Rosalind Advisors, Inc. | 3,671,550 | $7.86M |
| AIGH Capital Management LLC | 3,197,394 | $6.84M |
| Nantahala Capital Management, LLC | 2,712,443 | $5.80M |
| Barclays PLC | 120,497 | $257.9K |
| Pale Fire Capital SE | 25,030 | $53.6K |
| Integrated Wealth Concepts LLC | 20,000 | $42.8K |
| Susquehanna International Group, LLP | 16,134 | $34.5K |
| Commerce Bank | 14,000 | $30.0K |
| Tower Research Capital LLC (TRC) | 2,285 | $4.89K |
| Citadel Advisors LLC | 303 | $648 |
Not filed for Q4 2024 yet (1)
Institutions that held Cellectar Biosciences, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Raymond James Financial Services Advisors, Inc. | 30,000 | $64.2K |